Umlaut.bio, a German/Swiss oncology/immunology BioTech company developing tRNA-modifying compact molecules, announced the extension of its pre-Seed financing to ~€3 million…
Read More

Umlaut.bio, a German/Swiss oncology/immunology BioTech company developing tRNA-modifying compact molecules, announced the extension of its pre-Seed financing to ~€3 million…
Read More